O-7200 Osimertinib, Free Base, >99%

Solubility: Soluble in DMSO.

SMR-104 SMR-103 SMR-102 SMR-101

View the SDS for this product

• Osimertinib, also known as AZD9291, is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). EGFR TKIs have been used to treat patients with non-small-cell lung cancer (NSCLC) harboring sensitizing mutations. However, resistance develops in many patients, mainly because of the T790M mutation leading to disease progression. Furthermore, EGFR wild type receptor inhibition inherent with these EGFR TKIs can lead to dose-limiting toxicities. Osimertinib is an early, mutant selective, irreversible inhibitor of both EGFR mutant (EGFRm+) sensitizing and T790M resistance mutations with selectivity over the wild type form of the receptor. Finlay M.R., et al. "Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor." J. Med. Chem. 57: 8249-8267 (2014).
• This research compound is the free base form of osimertinib. We also offer the methanesulfonate salt and dimethansulfonate salt forms; please see Osimertinib, Methanesulfonate Salt, Cat. No. O-7233 and Osimertinib, Dimethanesulfonate Salt Cat. No. O-7266. These two other forms of osimertinib will be available shortly.
• Osimertinib inhibited EGFR phosphorylation in EGFR-bearing cells harboring sensitizing EGFR mutants with mean IC50 values ranging from 13 to 54 nM. It also potently inhibited phosphorylation of EGFR in T790M+ mutant cell lines, with mean IC50 potency less than 15 nM. However, it was less potent at inhibiting phosphorylation of EGFR in wild-type cell lines with mean IC50 range of 480 to 1,865 nM. Osimertinib demonstrated profound and sustained tumor regression in EGFR-mutant tumor xenograft and transgenic models. The clinical activities of osimertinib were initially confirmed with the treatment of two patients with advanced EGFRm(+) T790M(+) non-small-cell lung cancer (NSCLC). Cross D.A., et al. "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer." Cancer Discov. 4: 1046-1061 (2014).
• A phase I clinical study showed that osimertinib had robust efficacy in EGFR mutant NSCLC patients with acquired resistance to EGFR-TKIs. Overall response rate (ORR) was 51%. The ORR was 64% in 89 EGFR T790M positive patients and 23% in 43 EGFR T790M negative patients. The overall disease control rate was 96% in T790M positive patients. It was well tolerated. Jiang T. and Zhou C. "Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer." Transl. Lung Cancer Res. 6: 370-372 (2014).
• This osimertinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt form is 1421373-66-1 and a CAS number for the dimethansulfonate salt form has not been assigned as of March 2, 2016.
• Another CAS number previously assigned to Osimertinib, namely 1610419-47-0, has been deleted by CAS and is no longer in use.
• Osimertinib is the active ingredient in the drug product sold under the trade name Tagrisso®. This drug is currently approved in at least one country for use in patients with metastatic NSCL whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 L858R mutations.  NOTE: THE OSIMERTINIB, FREE BASE SOLD BY LC LABORATORIES FOR RESEARCH IS NOT TAGRISSO®, AND IS NOT FOR HUMAN USE.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.